Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.45 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038514 | 0.74 | CHRNB2 (0.51) | CHRNB2CHRNA6CHRNA4 | |
| SCHEMBL17147930 | 0.72 | SLC6A4 (0.53) | SLC6A4 | |
| SCHEMBL19606347 | 0.70 | PSMB5 (0.57) | SLC6A4CHRNB2CHRNA4 | |
| SCHEMBL25005282 | 0.70 | SLC6A4 (0.57) | SLC6A4 | |
| SCHEMBL13850677 | 0.70 | SLC6A4 (0.46) | SLC6A4CHRNB2CHRNA4 | |
| SCHEMBL3384597 | 0.69 | HTR3A (0.58) | CHRNB2CHRNA4 | |
| SCHEMBL31406195 | 0.68 | SLC6A2 (0.68) | SLC6A4 | |
| SCHEMBL9456721 | 0.67 | HTR3A (0.56) | SLC6A4 | |
| SCHEMBL3088721 | 0.67 | PSMB5 (0.61) | SLC6A4 | |
| SCHEMBL9200137 | 0.67 | HTR3E (0.57) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118326-A1 | Nicotinic Acetylcholine Receptor Modulators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-07 | — | — | US | disclosed |
| WO-2009058120-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SRI INTERNATIONAL (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118326-A1 | Nicotinic Acetylcholine Receptor Modulators | CHRNA10, CHRNA6, CHRNA5 | SLC6A4 1198/4885CHRNB2 12/4885CHRNA6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.